Last reviewed · How we verify

MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals — Portfolio Competitive Intelligence Brief

MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
APOKYN APOKYN marketed Dopaminergic Agonist D(2) dopamine receptor Neuroscience
apomorphine infusion apomorphine infusion phase 3

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Pfizer · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals:

Cite this brief

Drug Landscape (2026). MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mdd-us-operations-llc-a-subsidiary-of-supernus-pharmaceuticals. Accessed 2026-05-17.

Related